Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Amgen Inc Set to Possibly Rebound After Yesterday's Selloff of 1.17%

Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $199.59 to a high of $203.44. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $202.17...

AMGN : 199.08 (-2.13%)
Amgen Presents Positive Data From Rituxan Biosimilar Study

Amgen (AMGN) markets Mvasi and Kanjinti, biosimilar versions of Avastin and Herceptin, respectively in the United States, and Kanjinti and Amgevita, biosimilar of Humira, in the EU.

AGN : 158.96 (-1.22%)
ABBV : 65.97 (-2.30%)
RHHBY : 34.4100 (-0.43%)
AMGN : 199.08 (-2.13%)
Asymmetry Capital Management Announces Hiring of Alex Virgilio, Ph.D.

Asymmetry Capital Management, L.P., an alternative asset management firm launched in 2013 by Scott Kay, is pleased to announce that Alex Virgilio, Ph.D. has joined the Asymmetry Investment Team as an Analyst...

AMGN : 199.08 (-2.13%)
Amgen (AMGN) Moves to Buy: Rationale Behind the Upgrade

Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AMGN : 199.08 (-2.13%)
Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798, a biosimilar candidate to Rituxan®...

AGN : 158.96 (-1.22%)
AMGN : 199.08 (-2.13%)
Global Colorectal Cancer Market Outlook (2017-2026)

According to Stratistics MRC, the Global Colorectal Cancer Market is accounted for $9.22 billion in 2017 and is expected to reach $13.01 billion by 2026 growing at a CAGR of 3.9% during the forecast period....

EPGNY : 9.2600 (+0.11%)
AMGN : 199.08 (-2.13%)
Global Pancreatic Cancer Market Outlook (2017-2026)

According to Stratistics MRC, the Global Pancreatic Cancer market is accounted for $1,904.20 million in 2017 and is expected to reach $4,728.19 million by 2026 growing at a CAGR of 10.6% during the forecast...

CLVS : 5.95 (+1.02%)
TEVA : 7.05 (-2.89%)
AMGN : 199.08 (-2.13%)
CELGZ : 0.55 (+1.97%)
PFE : 34.34 (-2.11%)
Record Revenues, Milestone Achievements Indicate Strength, Potential of Biotech Sector

Biotech and biopharma industry leaders are posting record financials and hitting milestone markers in their research and growth, good indicators of a strong market with potential for robust returns on...

CELG : 93.99 (-1.80%)
CELGZ : 0.55 (+1.97%)
AMGN : 199.08 (-2.13%)
GNPX : 0.94 (-2.87%)
BIIB : 225.85 (-2.68%)
BMY : 46.58 (-2.67%)
Here's Why Allergan is Outperforming Its Industry Of Late

Allergan's (AGN) pending merger with AbbVie, positive pipeline and regulatory updates and increase in sales guidance twice are driving shares up this year.

AGN : 158.96 (-1.22%)
ABBV : 65.97 (-2.30%)
RHHBY : 34.4100 (-0.43%)
AMGN : 199.08 (-2.13%)
California Life Sciences Association Adds Substantial Depth to Board with Several New Appointments

California Life Sciences Association (CLSA), the trade association representing California's life sciences sector, today announced the appointment of several new members to CLSA's Board of Directors. Joining...

MDT : 106.05 (-1.65%)
AMGN : 199.08 (-2.13%)
Axsome Therapeutics Appoints David Marek as Chief Commercial Officer

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the appointment...

AMGN : 199.08 (-2.13%)
AXSM : 24.85 (-1.51%)
AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA

AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.

NVS : 88.44 (-0.63%)
ABBV : 65.97 (-2.30%)
AMGN : 199.08 (-2.13%)
BIIB : 225.85 (-2.68%)
Amgen (AMGN) Soars to 52-Week High, Time to Cash Out?

Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

GHDX : 73.26 (-0.35%)
AMGN : 199.08 (-2.13%)
BIIB : 225.85 (-2.68%)
ALXN : 115.33 (-6.61%)
Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More

Key highlights of the past week include collaborations, and other regulatory and pipeline news.

AMRN : 15.21 (-2.25%)
ALNY : 81.89 (-0.33%)
GILD : 62.51 (-2.66%)
REGN : 286.85 (-2.77%)
AMGN : 199.08 (-2.13%)
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

CELG : 93.99 (-1.80%)
VRTX : 180.18 (-2.20%)
GILD : 62.51 (-2.66%)
REGN : 286.85 (-2.77%)
AMGN : 199.08 (-2.13%)
ALXN : 115.33 (-6.61%)
Here's Why Amgen Stock is Outperforming Its Industry Of Late

Favorable patent ruling related to Enbrel and strong second-quarter results drive Amgen (AMGN) stock 22.6% higher in the past three months.

AGN : 158.96 (-1.22%)
NVS : 88.44 (-0.63%)
RHHBY : 34.4100 (-0.43%)
AMGN : 199.08 (-2.13%)
Mergers & Acquisitions Take Center Stage in Biotech Industry

Mergers & Acquisitions Take Center Stage in Biotech Industry

CELG : 93.99 (-1.80%)
VRTX : 180.18 (-2.20%)
GILD : 62.51 (-2.66%)
REGN : 286.85 (-2.77%)
AMGN : 199.08 (-2.13%)
BIIB : 225.85 (-2.68%)
ALXN : 115.33 (-6.61%)
Should Value Investors Choose Amgen (AMGN) Stock Now?

Let's see if Amgen (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.

AMGN : 199.08 (-2.13%)
Is Amgen (AMGN) Outperforming Other Medical Stocks This Year?

Is (AMGN) Outperforming Other Medical Stocks This Year?

AMGN : 199.08 (-2.13%)
Will Amgen Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Amgen.

AMGN : 199.08 (-2.13%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
AIZ -4.33 , WELL -1.15 , SBAC +0.27 , CCI +0.23 , SO -0.77
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar